Phase I Clinical Study on the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Characteristics of Single/Multiple Dose Escalation of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease
Latest Information Update: 30 Dec 2024
At a glance
- Drugs TQC 3721 (Primary)
 - Indications Chronic obstructive pulmonary disease
 - Focus Adverse reactions
 - Sponsors Chia Tai Tianqing Pharmaceutical Group
 
Most Recent Events
- 30 Dec 2024 New trial record